Technology ID
TAB-4966
Licensing Recommendation for CHO-DG44 Cell Adaptation for RSV F Protein Expression
E-Numbers
E-177-2018-0
Lead Inventor
Chen, Peifeng
Lead IC
NIAID
Co-Inventors
Ghosh, Mridul
Nagy, Attila
Horwitz, Joseph
Chen, Mingzong
Carey, Elizabeth
ICs
NIAID
Applications
Vaccines
Therapeutic Areas
Oncology
Infectious Disease
Development Stages
Discovery
Research Products
Human Cell Lines
The technology involves the adaptation of CHO-DG44 cells to ActiCHO P medium, improving their doubling time and suitability for generating stable cell lines for GMP purposes. These stable cell lines are designed for expressing the RSV F protein stabilized in the prefusion conformation, including the DS-Cav1 mutation, developed by the Vaccine Research Center. This adaptation process aims to create an optimal host line for manufacturing stabilized RSV F, ensuring stable expression and high protein yields without compromising function or stability. The technology is fully developed and serves as a valuable research tool for various commercial entities developing RSV prefusion F vaccines, such as GSK and China National Biotech Group.
Commercial Applications
The technology's potential applications extend beyond RSV vaccine development, encompassing a wide range of biopharmaceutical and research endeavors. The adapted CHO-DG44 cells can serve as a versatile platform for the production of various biologics beyond the RSV F protein, including other viral antigens, therapeutic proteins, and monoclonal antibodies. This flexibility makes the technology valuable for addressing diverse medical needs, from infectious diseases to oncology and beyond. Furthermore, the stable expression and high protein yields achievable with this technology make it an attractive option for biopharmaceutical companies seeking efficient and reliable cell lines for the development and production of novel biologics.
Competitive Advantages
The technology's competitive advantages lie in its ability to significantly enhance the production efficiency and stability of the RSV F protein, a crucial component in RSV vaccine development. By adapting CHO-DG44 cells to ActiCHO P medium, the technology offers improved doubling times, which can lead to faster and more cost-effective production processes. Additionally, the stable cell lines developed using this technology exhibit high expression levels of the RSV F protein in its prefusion conformation, a critical requirement for vaccine efficacy. This innovation not only streamlines the manufacturing process but also ensures that the produced vaccine maintains its functional integrity and stability, providing a competitive edge in the development of RSV vaccines.
Licensing Contact: